dc.contributor.author
Auer, Timo Alexander
dc.contributor.author
Walter-Rittel, Thula
dc.contributor.author
Geisel, Dominik
dc.contributor.author
Schöning, Wenzel
dc.contributor.author
Schmelzle, Moritz
dc.contributor.author
Müller, Tobias
dc.contributor.author
Sinn, Bruno
dc.contributor.author
Denecke, Timm
dc.contributor.author
Hamm, Bernd
dc.contributor.author
Fehrenbach, Uli
dc.date.accessioned
2023-03-16T12:06:36Z
dc.date.available
2023-03-16T12:06:36Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/38416
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-38134
dc.description.abstract
BackgroundRecent studies provide evidence that hepatocellular adenomas (HCAs) frequently take up gadoxetic acid (Gd-EOB) during the hepatobiliary phase (HBP). The purpose of our study was to investigate how to differentiate between Gd-EOB-enhancing HCAs and focal nodular hyperplasias (FNHs). We therefore retrospectively included 40 HCAs classified as HBP Gd-EOB-enhancing lesions from a sample of 100 histopathologically proven HCAs in 65 patients. These enhancing HCAs were matched retrospectively with 28 FNH lesions (standard of reference: surgical resection). Two readers (experienced abdominal radiologists blinded to clinical data) reviewed the images evaluating morphologic features and subjectively scoring Gd-EOB uptake (25-50%, 50-75% and 75-100%) for each lesion. Quantitative lesion-to-liver enhancement was measured in arterial, portal venous (PV), transitional and HBP. Additionally, multivariate regression analyses were performed.
ResultsSubjective scoring of intralesional Gd-EOB uptake showed the highest discriminatory accuracies (AUC: 0.848 (R#1); 0.920 (R#2)-p<0.001) with significantly higher uptake scores assigned to FNHs (Cut-off: 75%-100%). Typical lobulation and presence of a central scar in FNH achieved an accuracy of 0.750 or higher in at least one reader (lobulation-AUC: 0.809 (R#1); 0.736 (R#2); central scar-AUC: 0.595 (R#1); 0.784 (R#2)). The multivariate regression emphasized the discriminatory power of the Gd-EOB scoring (p=0.001/OR:22.15 (R#1) and p<0.001/OR:99.12 (R#2). The lesion-to-liver ratio differed significantly between FNH and HCA in the PV phase and HBP (PV: 132.9 (FNH) and 110.2 (HCA), p=0.048 and HBP: 110.3 (FNH) and 39.2 (HCA), p<0.001)), while the difference was not significant in arterial and transitional contrast phases (p>0.05).
ConclusionEven in HBP-enhancing HCA, characterization of Gd-EOB uptake was found to provide the strongest discriminatory power in differentiating HCA from FNH. Furthermore, a lobulated appearance and a central scar are more frequently seen in FNH than in HCA.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Magnetic resonance imaging
en
dc.subject
Focal nodular hyperplasia
en
dc.subject
Hepatocellular adenoma
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
28
dcterms.bibliographicCitation.doi
10.1186/s12880-021-00552-0
dcterms.bibliographicCitation.journaltitle
BMC Medical Imaging
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
21
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33588783
dcterms.isPartOf.eissn
1471-2342